Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2123-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0002 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26 |
filingDate |
2017-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3eded024e4a8faaf147c93b78ef7d8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d36e70412743c833eede876a9193e2a4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af2b239690cd15ccf84072a5693657e0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33d89ea73f8ac3f68736e7784052cab8 |
publicationDate |
2017-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CY-1118616-T1 |
titleOfInvention |
LIXISENATIDE AS ADDITIONAL TREATMENT IN BASIC INSULIN IN TYPE 2 DIABETES |
abstract |
The present invention relates to a pharmaceutical combination for use in glycemic control in patients with type 2 diabetes. The combination comprises lipixenatide (AVEOOIO), a GLP-1 agonist and basal insulin. |
priorityDate |
2011-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |